Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : $132.0 million
Deal Type : Termination
ObsEva Recovers Full Worldwide Rights on Nolasiban
Details : Under the termination of agreement with Yuyuan, ObsEva recovered full worldwide rights on OBE001 (nolasiban), a novel, oral oxytocin receptor antagonist being developed to improve pregnancy and live birth rates in women undergoing embryo transfer after i...
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : $132.0 million
Deal Type : Termination
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Details : Nolasiban (OBE001), an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This increases the chance of successful pregnancy and ...
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Yuyuan Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21
Details : Results support the further evaluation of higher doses and/or alternate regimens of nolasiban. ObsEva is partnering with YuYuan BioScience Technology, a Chinese company, for the development of nolasiban.
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Yuyuan Bioscience Technology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This sublicense agreement aims to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2020
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Yuyuan Bioscience Technology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Yuyuan Bioscience Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nolasiban, a novel, oral oxytocin receptor antagonist, is being developed for improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization (IVF). Two Phase 3 studies have been completed in Europe.
Product Name : OBE001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2020
Lead Product(s) : Nolasiban
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Yuyuan Bioscience Technology
Deal Size : Inapplicable
Deal Type : Inapplicable